U.S. markets closed
  • S&P 500

    3,841.85
    +73.38 (+1.95%)
     
  • Dow 30

    31,495.84
    +571.70 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,182.49
    +35.56 (+1.66%)
     
  • Crude Oil

    66.29
    +2.46 (+3.85%)
     
  • Gold

    1,697.10
    -3.60 (-0.21%)
     
  • Silver

    25.25
    -0.22 (-0.85%)
     
  • EUR/USD

    1.1919
    -0.0060 (-0.50%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3844
    -0.0049 (-0.36%)
     
  • USD/JPY

    108.3550
    +0.3790 (+0.35%)
     
  • BTC-USD

    49,234.17
    +1,099.14 (+2.28%)
     
  • CMC Crypto 200

    983.29
    +40.11 (+4.25%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

PAOG Takes Major CBD Pharmaceutical Development Step Forward

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Sandusky, Ohio--(Newsfile Corp. - January 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product.

PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough, Massachusetts. PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and Drug Administration (FDA).

On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Learn more about PAOG at www.paogroupinc.com.

Learn more about Veristat at www.veristat.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71399